Concepedia

Matthew Scaramozza

MS

Statistics

Publications

12

Citations

643

H-Index

11

Active since

2014

Affiliations

Pfizer (United States)(Current)

Biogen (United States)

NeuroRx Research (Canada)

McGill University

University of Ottawa

Matthew Scaramozza is an author at Pfizer (United States) specializing in medicine, dermatology, and clinical trials.

ORCID

Top concepts

Publications per year

2014–2023

12

Publications

12

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

Thomas Leist, Giancarlo Comi, Bruce Cree et al. · The Lancet Neurology · 2014 · 237 citations

, , +8

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

Christopher Banfield, Matthew Scaramozza, Weidong Zhang et al. · The Journal of Clinical Pharmacology · 2017 · 90 citations · Full text

Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis

Karen Page, Mayte Suárez‐Fariñas, Maria Suprun et al. · Journal of Investigative Dermatology · 2020 · 53 citations

, , +12

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis

Patrick Vermersch, Matthew Scaramozza, Seth Levin et al. · JAMA Network Open · 2022 · 50 citations · Full text

Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions

Colm Elliott, Douglas L. Arnold, H. Chen et al. · American Journal of Neuroradiology · 2020 · 41 citations · Full text

Rows per page

1–5 of 12